
MHE October 2023



Laws since 1996 have sought to assure that coverage of behavioral health treatments does not take a back seat to physical medicine. Amid a national crisis in mental illness and addiction, that new world of equality has not arrived. But is it on the way?

Two drugs that target the c-MET protein are in phase 3 trials.

Payers and hospitals are at odds over proposals that would level out payments to hospital outpatient departments and physician offices.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Early trial of linvoseltamab shows promise for newly diagnosed multiple myeloma patients | ASH 2025
2
Gene therapy in the real world: High priced, a long process and still relatively few patients | ASH 2025
3
Findings suggest linvoseltamab could be a useful new option for new multiple myeloma patients | ASH 2025
4
Jaypirca shows promise as a frontline treatment for CLL/SLL patients | ASH 2025
5




